Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products.
When a trained pharmacist screened patients for eligibility, cancer practices were able to enroll nearly twice the number of participants each month than they were before this strategy was implemented.
Oncologists at ASCO cheered data showing the drug significantly cut the risk of disease progression or death, but experts wondered how existing HER2 testing paradigms will change in response.
Researchers presented data at ASCO on therapies for NSCLC patients with EGFR exon 20 insertions, MET exon 14 skipping, and those with EGFR activating mutations out of standard options.
Based on encouraging data in mice, investigators are assessing if temozolomide-cisplatin can make patients' "cold" tumors respond to checkpoint blockade.
Despite the registry's growth in content and utility, currently more than 80 percent of the clinical and genomic data comes from white patients, which AACR wants to change.
The NCI-funded project, which was delayed due to the pandemic, is poised to begin, and aims to provide actionable data and build a reference genome for American Indians.
Data presented at the AACR annual meeting suggests that some recurrent breast cancers after DCIS are actually new primary tumors in some high-risk patients.
A woman worried about her cancer risks gets tested through 23andMe upon the recommendation of a "holistic doctor" but isn't prepared for what the testing reveals.
The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.
A woman is sent for pancreatic cancer screening based on testing from a lab that refuses to share technical data and a doctor's misinterpretation of a VUS as pathogenic.